-
ASH 2024 | Dr. Shaji Kumar Discusses Advances and Management Recommendations for Newly Diagnosed Multiple Myeloma
1. Advances and Challenges in Treating Newly Diagnosed MM Hematology Frontier: This session focused on Newly Diagnosed Multiple Myeloma: Many Choices and More Questions. As the session chair, could you…
-
A New Year, A New Chapter in Hematology
As we step into 2025, we reflect on the incredible progress made in hematology and set our sights on the breakthroughs to come. This heartfelt message celebrates the dedication of our doctors, researchers, and patients who inspire hope and innovation every day. Let’s work hand in hand to bring new solutions, brighter outcomes, and life-changing…
-
93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH
The 66th Annual Meeting of the American Society of Hematology (ASH), the largest global academic event in the field of hematology, took place from December 7 to 10, 2024, in San Diego, USA. The event brought together leading researchers and clinicians from around the world to discuss cutting-edge advancements in hematology, innovative therapies, and ongoing…
-
N Engl J Med | Professors Lei Zhang and Renchi Yang’s Team Unveils Efficacy, Safety, and Mechanism of a Novel CD38 Monoclonal Antibody in ITP Patients
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production due to antibody-mediated mechanisms. Current first-line therapies for ITP include glucocorticoids and immunoglobulins, while second-line options often involve thrombopoietin receptor agonists (TPO-RAs), CD20 monoclonal antibodies, and splenectomy. The introduction of CD20 monoclonal antibody therapy over the past…
-
Leukemia | Professors Junren Chen, Erlie Jiang, Zimin Sun’s Team Validates New Standard for Calculating CD34+ Cell Dose
Recently, the team led by Professor Junren Chen from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, along with Professor Zimin Sun’s team from The First Affiliated Hospital of the University of Science and Technology of China, conducted a retrospective analysis of 620 unrelated cord blood transplant cases in Anhui.
-
JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng
Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore…
-
ASH 2024 | Annual Hemoglobinopathy Highlights and ASH President’s Vision for Global Hematology
Reflections from ASH President Mohandas Narla Dr. Mohandas Narla: I have been involved in ASH activities for 49 years, and ASH has consistently prioritized presenting novel and innovative content at…
-
ASH 2024 | Dr. Gilles Salles from MSK on Advancing Lymphoma Treatment
1. Could you briefly introduce yourself, your field of expertise, and your research focus? Dr. Gilles Salles: Hello, everyone. I’m Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center (MSK).…
Connecting Medical Expertise through Media